RTTNews | Jun 29, 2021 10:14AM EDT

10:14 Tuesday, June 29, 2021 (RTTNews.com) - Shares of biotechnology company Iovance Biotherapeutics, Inc. (IOVA) are down 4 percent on Tuesday's trading as the company released clinical data on its tumor infiltrating lymphocyte or TIL therapy LN-145 conducted on patients with metastatic non-small cell lung cancer.

The company said that the overall response rate or ORR was 21.4 percent and and the disease control rate or DCR was 64.3 percent following one-time treatment with LN-145 monotherapy. Iovance Biotherapeutics plans to give additional data regarding the study during the second half of the year.

Currently trading at $26.46, the stock has traded between $15.88 and $54.21 during the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3205781/iovance-biotherapeutics-down-4-releases-clinical-data-for-its-til-therapy-ln-145.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved